Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 1, 2012, Pages 133-137

  Zificsak, Craig A ^a   Gingrich, Diane E ^a   Breslin, Henry J ^a   Dunn, Derek D ^a   Milkiewicz, Karen L ^a   Theroff, Jay P ^a   Thieu, Tho V ^a   Underiner, Ted L ^a   Weinberg, Linda R ^a   Aimone, Lisa D ^a   Albom, Mark S ^a   Mason, Jennifer L ^a   Saville, Lisa ^a   Husten, Jean ^a   Angeles, Thelma S ^a   Finn, James P ^a   Jan, Mahfuza ^a   O'Kane, Teresa M ^a   Dobrzanski, Pawel ^a   Dorsey, Bruce D ^a  

^a CEPHALON INC   (United States)

Author keywords

FAK; Inhibitors; JAK2; Kinase

Indexed keywords

ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; JANUS KINASE 2; PHOSPHOTRANSFERASE INHIBITOR;

ARTICLE; CARCINOGENESIS; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; METHYLATION; NITRATION; NONHUMAN; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DISEASE PROGRESSION; DRUG DESIGN; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; INHIBITORY CONCENTRATION 50; JANUS KINASE 2; MICE; MODELS, CHEMICAL; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84655162074     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.11.049     Document Type: Article

References (16)

1. A. Tefferi, and A. Pardanani Blood Rev. 25 2011 229
2. H. Yu, and R. Jove Nat. Rev. Cancer 4 2004 97
3. E. Devarajan, and S. Huang Curr. Mol. Med. 9 2009 626
4. F. Santos, and S. Verstovsek Blood Rev. 25 2011 53
5. M. Hedvat, D. Huszar, A. Herrmann, J.M. Gozgit, A. Schroeder, A. Sheehy, R. Buettner, D. Proia, C.M. Kowolik, H. Xin, B. Armstrong, G. Bebernitz, S. Weng, L. Wang, M. Ye, K. McEachern, H. Chen, D. Morosini, K. Bell, M. Alimzhanov, S. Ioannidis, P. McCoon, Z.A. Cao, H. Yu, R. Jove, and M. Zinda Cancer Cell 16 2009 487
6. A. Quintás-Cardama, K. Vaddi, P. Liu, T. Manshouri, J. Li, P.A. Scherle, E. Caulder, X. Wen, Y. Li, P. Waeltz, M. Rupar, T. Burn, Y. Lo, J. Kelley, M. Covington, S. Shepard, J.D. Rodgers, P. Haley, H. Kantarjian, J.S. Fridman, and S. Verstovsek Blood 115 2010 3109
7. Incyte press release August 3, 2011.
8. T. Thieu, J.A. Sclafani, D.V. Levy, A. McLean, H.J. Breslin, G.R. Ott, R.P. Bakale, and B.D. Dorsey Org. Lett. 13 2011 4204
9. G.R. Ott, G.J. Wells, T.V. Thieu, M.R. Quail, J.G. Lisko, E.F. Mesaros, D.E. Gingrich, A.K. Ghose, W. Wan, L. Lu, M. Cheng, M.S. Albom, T.S. Angeles, Z. Huang, L.D. Aimone, M.A. Ator, B.A. Ruggeri, and B.D. Dorsey J. Med. Chem. 54 2011 6328
10. Mesaros, E. F.; Thieu, T. V.; Wells, G. J.; Zificsak, C. A.; Wagner, J. C.; Breslin, H. J.; Tripathy, R.; Diebold, J. L.; McHugh, R. J.; Wohler, A. T.; Quail, M. R.; Wan, W.; Lu, L.; Huang, Z.; Albom, M. S.; Angeles, T. S.; Wells-Knecht, K. J.; Aimone, L. D.; Cheng, M.; Ator, M. A.; Ott, G. R.; Dorsey, B. D. J. Med. Chem, accepted for publication.
11. H.-S. Choi, Z. Wang, W. Richmond, X. He, K. Yang, T. Jiang, T. Sim, D. Karanewsky, X.-J. Gu, V. Zhou, Y. Liu, O. Ohmori, J. Caldwell, N. Gray, and Y. He Bioorg. Med. Chem. Lett. 16 2006 2173
12. P. Furet, M. Gerspacher, and C. Pissot-Soldermann Bioorg. Med. Chem. Lett. 20 2010 1858
13. G.R. Ott, R. Tripathy, M. Cheng, R. McHugh, A.V. Anzalone, T.L. Underiner, M.A. Curry, M.R. Quail, L. Lu, W. Wan, T.S. Angeles, M.S. Albom, L.D. Aimone, M.A. Ator, B.A. Ruggeri, and B.D. Dorsey ACS Med. Chem. Lett. 1 2010 493
14. The o-methoxy group in 2 is accommodated by the gatekeeper+2 residue in FAK (leucine) but not in JAK2 (tyrosine). For a similar binding analysis, see: A.V. Galkin, J.S. Melnick, S. Kim, T.L. Hood, N. Li, L. Li, G. Xia, R. Steensma, G. Chopiuk, J. Jiang, Y. Wan, P. Ding, Y. Liu, F. Sun, P.G. Schultz, N.S. Gray, and M. Warmuth Proc. Natl. Acad. Sci. U.S.A. 104 2007 270
15. R.K. Arvela, and N.E. Leadbeater Synlett 2003 1145
16. For a full listing of the Invitrogen results, see the Supplementary data.